PWA
INDV icon

Physician Wealth Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

Physician Wealth Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15K Buy
+28
New +$1.02K ﹤0.01% 1774

Other funds holding INDV

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Physician Wealth Advisors's INDV Position: Q2 2026 in Review

Physician Wealth Advisors opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 28 shares worth $1.15K. The stake represents ﹤0.01% of the portfolio and ranks #1774 among its holdings.

31 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Physician Wealth Advisors held 28 shares of Indivior Pharmaceuticals worth $1.15K as of Q2 2026.
  • Indivior Pharmaceuticals was a new Physician Wealth Advisors position in Q2 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Physician Wealth Advisors's portfolio in Q2 2026, its #1774 holding.
  • 31 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Physician Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.